Protein misfolding diseases: Prospects of pharmacological treatment

Clinical Genetics

Volumn 93, Issue 3, 2018, Pages 450-458

  Gamez A ^a   Yuste Checa, P ^a   Brasil, S ^a   Briso Montiano, A ^a   Desviat, L R ^a   Ugarte, M ^a   Perez Cerda C ^a   Perez B ^a  

^a CSIC   (Spain)

Author keywords

conformational diseases; congenital disorders of glycosylation; inborn errors of metabolism; misfolding diseases; pharmacological chaperones; protein folding; proteostasis regulators

Indexed keywords

CHAPERONE; PHOSPHOMANNOMUTASE; STRUCTURAL PROTEIN;

CONGENITAL DISORDER OF GLYCOSYLATION; CYTOSOL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME DEFICIENCY; GAIN OF FUNCTION MUTATION; GENETIC DISORDER; HUMAN; LYSOSOME STORAGE DISEASE; METABOLIC DISORDER; PHOSPHOMANNOMUTASE 2 DEFICIENCY; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN MISFOLDING; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECT; GENETIC PREDISPOSITION; GLYCOSYLATION; METABOLISM; MITOCHONDRION; MUTATION; PROTEOSTASIS DEFICIENCY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION; HUMANS; MITOCHONDRIA; MUTATION; PROTEOSTASIS DEFICIENCIES;

EID: 85037361802     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.13088     Document Type: Review

References (129)

1. Balch WE, Morimoto RI, Dillin A. Adapting proteostasis for disease intervention. Science. 2008;319:916–919.
2. Wang YJ, Di XJ, Mu TW. Using pharmacological chaperones to restore proteostasis. Pharmacol Res. 2014;83:3-9.
3. Chambers JE, Marciniak SJ. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 2. Protein misfolding and ER stress. Am J Physiol Cell Physiol. 2014;307:C657-C670.
4. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324-332.
5. Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996;381:571-579.
6. Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and quality control. Science. 2016;353:aac4354.
7. Martinez A, Calvo AC, Teigen K, Pey AL. Rescuing proteins of low-kinetic stability by chaperones and natural ligands phenylketonuria, a case study. Prog Mol Biol Transl Sci. 2008;83:89–134.
8. Carrell RW, Lomas DA. Conformational disease. Lancet. 1997;350:134-138.
9. Beissinger M, Buchner J. How chaperones fold proteins. Biol Chem. 1998;379:245-259.
10. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic. 2004;5:821–837.
11. Gregersen N. Protein misfolding disorders: pathogenesis and intervention. J Inherit Metab Dis. 2006;29:456-470.
12. Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis. 2014;37:505–523.
13. Jorge-Finnigan A, Aguado C, Sanchez-Alcudia R, et al. Functional and structural analysis of five mutations identified in methylmalonic aciduria cblB type. Hum Mutat. 2010;31:1033-1042.
14. Valastyan JS, Lindquist S. Mechanisms of protein-folding diseases at a glance. Dis Model Mech. 2014;7:9-14.
15. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science. 2011;334:1086-1090.
16. Varshavsky A. The ubiquitin system, an immense realm. Annu Rev Biochem. 2012;81:167-176.
17. Fredrickson EK, Gardner RG. Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. Semin Cell Dev Biol. 2012;23:530-537.
18. Mu TW, Ong DS, Wang YJ, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell. 2008;134:769-781.
19. Lee BS, Chen J, Angelidis C, Jurivich DA, Morimoto RI. Pharmacological modulation of heat shock factor 1 by antiinflammatory drugs results in protection against stress-induced cellular damage. Proc Natl Acad Sci U S A. 1995;92:7207–7211.
20. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280:33097-33100.
21. Neef DW, Jaeger AM, Thiele DJ. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov. 2011;10:930-944.
22. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15:243-249.
23. Westerheide SD, Bosman JD, Mbadugha BN, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem. 2004;279:56053-56060.
24. Trott A, West JD, Klaic L, et al. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell. 2008;19:1104-1112.
25. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94:471–480.
26. Vaughan CK, Neckers L, Piper PW. Understanding of the Hsp90 molecular chaperone reaches new heights. Nat Struct Mol Biol. 2010;17:1400-1404.
27. Ansar S, Burlison JA, Hadden MK, et al. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett. 2007;17:1984-1990.
28. Neef DW, Turski ML, Thiele DJ. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010;8:e1000291.
29. Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol. 2007;3:331-338.
30. Sarkar S, Rubinsztein DC. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst. 2008;4:895-901.
31. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467:179-184.
32. Krebs J, Agellon LB, Michalak M. Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: an integrated view of calcium signaling. Biochem Biophys Res Commun. 2015;460:114-121.
33. Egan ME, Glockner-Pagel J, Ambrose C, et al. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med. 2002;8:485-492.
34. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304:600-602.
35. Calamini B, Morimoto RI. Protein homeostasis as a therapeutic target for diseases of protein conformation. Curr Top Med Chem. 2012;12:2623-2640.
36. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519-529.
37. Ringe D, Petsko GA. What are pharmacological chaperones and why are they interesting? J Biol. 2009;8:80.
38. Aymami J, Barril X, Rodriguez-Pascau L, Martinell M. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases. Pharm Pat Anal. 2013;2:109–124.
39. Leidenheimer NJ, Ryder KG. Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharmacol Res. 2014;83:10-19.
40. Tropak MB, Blanchard JE, Withers SG, Brown ED, Mahuran D. High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol. 2007;14:153–164.
41. Jorge-Finnigan A, Brasil S, Underhaug J, et al. Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. Hum Mol Genet. 2013;22:3680-3689.
42. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629-9634.
43. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519-526.
44. Porto C, Ferrara MC, Meli M, et al. Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther. 2012;20:2201-2211.
45. Matalonga L, Gort L, Ribes A. Small molecules as therapeutic agents for inborn errors of metabolism. J Inherit Metab Dis. 2017;40:177-193.
46. Pey AL, Perez B, Desviat LR, et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat. 2004;24:388-399.
47. Staudigl M, Gersting SW, Danecka MK, et al. The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Hum Mol Genet. 2011;20:2628-2641.
48. Suzuki Y. Emerging novel concept of chaperone therapies for protein misfolding diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90:145-162.
49. Denny RA, Gavrin LK, Saiah E. Recent developments in targeting protein misfolding diseases. Bioorg Med Chem Lett. 2013;23:1935-1944.
50. Esposito S, Tosco A, Villella VR, Raia V, Kroemer G, Maiuri L. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Mol Cell Pediatr. 2016;3:13.
51. Dey I, Shah K, Bradbury NA. Natural compounds as therapeutic agents in the treatment cystic fibrosis. J Genet Syndr Gene Ther. 2016;7:284.
52. Norez C, Vandebrouck C, Bertrand J, et al. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br J Pharmacol. 2014;171:4831-4849.
53. Langman CB, Greenbaum LA, Sarwal M, et al. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol. 2012;7:1112-1120.
54. Charrier C, Rodger C, Robertson J, et al. Cysteamine (Lynovex(R)), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. Orphanet J Rare Dis. 2014;9:189.
55. Conn PM, Janovick JA. Drug development and the cellular quality control system. Trends Pharmacol Sci. 2009;30:228-233.
56. Lindquist SL, Kelly JW. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol. 2011;3:a004507.
57. Gregersen N, Bross P, Jorgensen MM, Corydon TJ, Andresen BS. Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders. J Inherit Metab Dis. 2000;23:441–447.
58. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382–W388.
59. Yuste-Checa P, Gamez A, Brasil S, et al. The effects of PMM2-CDG-causing mutations on the folding, activity, and stability of the PMM2 protein. Hum Mutat. 2015;36:851-860.
60. Huang A, Stultz CM. Finding order within disorder: elucidating the structure of proteins associated with neurodegenerative disease. Future Med Chem. 2009;1:467-482.
61. Cortez L, Sim V. The therapeutic potential of chemical chaperones in protein folding diseases. Prion. 2014;8:197–202.
62. Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci. 2014;15:233-249.
63. Diaz-Villanueva JF, Diaz-Molina R, Garcia-Gonzalez V. Protein folding and mechanisms of proteostasis. Int J Mol Sci. 2015;16:17193-17230.
64. Van Laar VS, Arnold B, Cassady SJ, Chu CT, Burton EA, Berman SB. Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization. Hum Mol Genet. 2011;20:927–940.
65. Ebrahimi-Fakhari D, Saidi LJ, Wahlster L. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies. Acta Neuropathol Commun. 2013;1:79.
66. Burch M, Blair E. The inheritance of hypertrophic cardiomyopathy. Pediatr Cardiol. 1999;20:313-316.
67. Baum J, Brodsky B. Folding of peptide models of collagen and misfolding in disease. Curr Opin Struct Biol. 1999;9:122-128.
68. Sorensen CB, Ladekjaer-Mikkelsen AS, Andresen BS, et al. Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis bullosa simplex: correlation between genotype and phenotype. J Invest Dermatol. 1999;112:184-190.
69. Werner NS, Windoffer R, Strnad P, Grund C, Leube RE, Magin TM. Epidermolysis bullosa simplex-type mutations alter the dynamics of the keratin cytoskeleton and reveal a contribution of actin to the transport of keratin subunits. Mol Biol Cell. 2004;15:990–1002.
70. Russell D, Andrews PD, James J, Lane EB. Mechanical stress induces profound remodelling of keratin filaments and cell junctions in epidermolysis bullosa simplex keratinocytes. J Cell Sci. 2004;117:5233–5243.
71. Monti P, Campomenosi P, Ciribilli Y, et al. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene. 2002;21:1641-1648.
72. Gregersen N, Bolund L, Bross P. Protein misfolding, aggregation, and degradation in disease. Mol Biotechnol. 2005;31:141-150.
73. Morava E, Rahman S, Peters V, Baumgartner MR, Patterson M, Zschocke J. Quo vadis: the re-definition of "inborn metabolic diseases". J Inherit Metab Dis. 2015;38:1003–1006.
74. Pey AL, Desviat LR, Gamez A, Ugarte M, Perez B. Phenylketonuria: genotype phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum Mutat. 2003;21:370–378.
75. Sarkissian CN, Gamez A, Scott P, et al. Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response? JIMD Rep. 2012;5:59-70.
76. Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370:504-510.
77. Lee P, Treacy EP, Crombez E, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008;146A:2851-2859.
78. Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009;154:700-707.
79. Pey AL, Ying M, Cremades N, et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest. 2008;118:2858-2867.
80. Santos-Sierra S, Kirchmair J, Perna AM, et al. Novel pharmacological chaperones that correct phenylketonuria in mice. Hum Mol Genet. 2012;21:1877-1887.
81. Melenovska P, Kopecka J, Krijt J, et al. Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate. J Inherit Metab Dis. 2015;38:287-294.
82. Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed Res Int. 2013;2013:687658.
83. Majtan T, Pey AL, Kraus JP. Kinetic stability of cystathionine beta-synthase can be modulated by structural analogs of S-adenosylmethionine: potential approach to pharmacological chaperone therapy for homocystinuria. Biochimie. 2016;126:6-13.
84. Pey AL, Majtan T, Sanchez-Ruiz JM, Kraus JP. Human cystathionine beta-synthase (CBS) contains two classes of binding sites for Sadenosylmethionine (SAM): complex regulation of CBS activity and stability by SAM. Biochem J. 2013;449:109–121.
85. Kopecka J, Krijt J, Rakova K, Kozich V. Restoring assembly and activity of cystathionine beta-synthase mutants by ligands and chemical chaperones. J Inherit Metab Dis. 2011;34:39–48.
86. Majtan T, Liu L, Carpenter JF, Kraus JP. Rescue of cystathionine betasynthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes. J Biol Chem. 2010;285:15866–15873.
87. Gupta S, Wang L, Anderl J, Slifker MJ, Kirk C, Kruger WD. Correction of cystathionine betasynthase deficiency in mice by treatment with proteasome inhibitors. Hum Mutat. 2013;34:1085–1093.
88. Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta. 1832;2013:1776-1783.
89. Yuste-Checa P, Brasil S, Gamez A, et al. Pharmacological chaperoning: a potential treatment for PMM2-CDG. Hum Mutat. 2017;38:160-168.
90. Matthijs G, Schollen E, Bjursell C, et al. Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat. 2000;16:386-394.
91. Vega AI, Perez-Cerda C, Desviat LR, Matthijs G, Ugarte M, Perez B. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia. Hum Mutat. 2009;30:795–803.
92. Vega AI, Perez-Cerda C, Abia D, et al. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis. 2011;34:929-939.
93. Perez B, Briones P, Quelhas D, et al. The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. JIMD Rep. 2011;1:117-123.
94. Brunetti-Pierri N, Lanpher B, Erez A, et al. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet. 2011;20:631-640.
95. Ferriero R, Manco G, Lamantea E, et al. Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis. Sci Transl Med. 2013;5:175ra131.
96. Lucas TG, Henriques BJ, Rodrigues JV, Bross P, Gregersen N, Gomes CM. Cofactors and metabolitesas potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim Biophys Acta. 2011;1812:1658–1663.
97. Henriques BJ, Lucas TG, Gomes CM. Therapeutic approaches using riboflavin in mitochondrial energy metabolism disorders. Curr Drug Targets. 2016;17:1527-1534.
98. Valenzano KJ, Khanna R, Powe AC, et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol. 2011;9:213-235.
99. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5:112–115.
100. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449–456.
101. Santos-Lozano A, Villamandos Garcia D, Sanchis-Gomar F, et al. Niemann-Pick disease treatment: a systematic review of clinical trials. Ann Transl Med. 2015;3:360.
102. Venier RE, Igdoura SA. Miglustat as a therapeutic agent: prospects and caveats. J Med Genet. 2012;49:591-597.
103. Scott LJ. Eliglustat: a review in Gaucher disease type 1. Drugs. 2015;75:1669-1678.
104. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441–471.
105. Marshall J, Sun Y, Bangari DS, et al. CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther. 2016;24:1019-1029.
106. Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med. 2009;11:425–433.
107. Villamizar-Schiller IT, Pabon LA, Hufnagel SB, et al. Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease. Eur J Med Genet. 2015;58:180-183.
108. Macias-Vidal J, Giros M, Guerrero M, et al. The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations. FEBS J. 2014;281:4450-4466.
109. 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. Chem Biol. 2011;18:766-776.
110. Chen CC, Keller M, Hess M, et al. A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV. Nat Commun. 2014;5:4681.
111. Tatti M, Motta M, Scarpa S, et al. BCM-95 and (2-hydroxypropyl)-beta-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap C-deficient fibroblasts. Hum Mol Genet. 2015;24:4198-4211.
112. Langman CB, Greenbaum LA, Grimm P, et al. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate. J Pediatr. 2014;165:528-533 e521.
113. Calamini B, Silva MC, Madoux F, et al. Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol. 2011;8:185-196.
114. Herrando-Grabulosa M, Mulet R, Pujol A, et al. Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems. PLoS One. 2016;11:e0147626.
115. Issa NT, Wathieu H, Ojo A, Byers SW, Dakshanamurthy S. Drug metabolism in preclinical drug development: a survey of the discovery process, toxicology, and computational tools. Curr Drug Metab. 2017. (Epub ahead of print).
116. Whitty A. Growing PAINS in academic drug discovery. Future Med Chem. 2011;3:797-801.
117. Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature. 2014;513:481-483.
118. Hay Mele B, Citro V, Andreotti G, Cubellis MV. Drug repositioning can accelerate discovery of pharmacological chaperones. Orphanet J Rare Dis. 2015;10:55.
119. Dawson G, Schroeder C, Dawson PE. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem Biophys Res Commun. 2010;395:66-69.
120. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;108:18843-18848.
121. Benjamin ER, Khanna R, Schilling A, et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther. 2012;20:717-726.
122. Motabar O, Liu K, Southall N, et al. High throughput screening for inhibitors of alpha-galactosidase. Curr Chem Genomics. 2010;4:67-73.
123. Motabar O, Sidransky E, Goldin E, Zheng W. Fabry disease – current treatment and new drug development. Curr Chem Genomics. 2010;4:50–56.
124. Steet R, Chung S, Lee WS, Pine CW, Do H, Kornfeld S. Selective action of the iminosugarisofagomine, a pharmacological chaperone for mutant forms of acid beta-glucosidase. Biochem Pharmacol. 2007;73:1376–1383.
125. Rigat BA, Tropak MB, Buttner J, et al. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy. Mol Genet Metab. 2012;107:203-212.
126. Clarke JT, Mahuran DJ, Sathe S, et al. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab. 2011;102:6-12.
127. Berardi AS, Pannuzzo G, Graziano A, Costantino-Ceccarini E, Piomboni P, Luddi A. Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients. Mol Genet Metab. 2014;112:294–301.
128. Xiao J, Westbroek W, Motabar O, et al. Discovery of a novel noniminosugar acid alpha glucosidase chaperone series. J Med Chem. 2012;55:7546-7559.
129. Feldhammer M, Durand S, Pshezhetsky AV. Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One. 2009;4:e7434.